205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3.98%
Revenue growth at 50-75% of ADI's 7.76%. Martin Whitman would worry about competitiveness or product relevance.
-2.45%
Negative gross profit growth while ADI is at 7.44%. Joel Greenblatt would examine cost competitiveness or demand decline.
-29.68%
Negative EBIT growth while ADI is at 153.47%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-29.68%
Negative operating income growth while ADI is at 153.47%. Joel Greenblatt would press for urgent turnaround measures.
97.89%
Net income growth at 75-90% of ADI's 117.75%. Bill Ackman would press for improvements to catch or surpass competitor performance.
120.00%
EPS growth similar to ADI's 125.00%. Walter Schloss would assume both have parallel share structures and profit trends.
120.00%
Diluted EPS growth 1.25-1.5x ADI's 100.00%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
-10.05%
Share reduction while ADI is at 0.14%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-10.05%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-7.61%
Dividend reduction while ADI stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
45.99%
OCF growth at 50-75% of ADI's 81.61%. Martin Whitman would question if the firm lags in monetizing sales effectively.
40.95%
FCF growth under 50% of ADI's 236.34%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
-16.58%
Negative 10Y revenue/share CAGR while ADI stands at 111.40%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-18.69%
Negative 5Y CAGR while ADI stands at 36.38%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-7.31%
Negative 3Y CAGR while ADI stands at 11.27%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
28.80%
10Y OCF/share CAGR under 50% of ADI's 267.95%. Michael Burry would worry about a persistent underperformance in cash creation.
-6.59%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
4.84%
Positive 3Y OCF/share CAGR while ADI is negative. John Neff might see a big short-term edge in operational efficiency.
131.58%
Below 50% of ADI's 330.24%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-90.07%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-54.01%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
290.57%
10Y equity/share CAGR at 50-75% of ADI's 452.01%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
58.71%
Below 50% of ADI's 186.00%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
37.68%
Below 50% of ADI's 84.41%. Michael Burry suspects a serious short-term disadvantage in building book value.
10.87%
Dividend/share CAGR of 10.87% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
2.63%
Dividend/share CAGR of 2.63% while ADI is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
8.23%
3Y dividend/share CAGR of 8.23% while ADI is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-2.08%
Firm’s AR is declining while ADI shows 0.81%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
0.37%
Inventory shrinking or stable vs. ADI's 12.20%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
-0.60%
Negative asset growth while ADI invests at 1.43%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
8.39%
BV/share growth above 1.5x ADI's 1.63%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
0.24%
Debt shrinking faster vs. ADI's 3.15%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
2.72%
R&D growth drastically higher vs. ADI's 4.10%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
4.75%
SG&A growth well above ADI's 7.67%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.